Q3 2025 Earnings Call Transcript October 28, 2025 Labcorp Holdings Inc. beats earnings expectations. Reported EPS is $4.18, ...
Guidance Updates -- Full-year 2025 revenue growth guidance was narrowed to 7.4%-8%, with Adjusted EPS guidance was set at $16 ...
StockStory.org on MSN
LH Q3 Deep Dive: Labcorp Sees Diagnostic Growth, Eyes Specialty Testing and Efficiency Initiatives
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its ...
MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights ...
7d
OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from ...
A merger would significantly change the competitive scene. With Quest and Labcorp being major players, their combination ...
A Labcorp team member draws blood from a patient.Labcorp Labcorp, one of the country’s largest providers of diagnostic ...
Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As the number of Americans at ...
Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and ...
Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback